Phase 3 ILLUMINATE 301 Trial of Idera’s IMO-2125 Combo Therapy For Advanced Melanoma Patients
at
A new Phase 3 trial for advanced melanoma patients who failed to respond to Opdivo (nivolumab) or Keytruda (pembrolizumab) is recruiting participants to evaluate Idera Pharmaceutical‘s experimental immunotherapy, IMO-2125, in combination with Yervoy (ipilimumab).